4//SEC Filing
Hawryluk P. Kent 4
Accession 0000950170-25-014494
CIK 0001776111other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:17 PM ET
Size
8.5 KB
Accession
0000950170-25-014494
Insider Transaction Report
Form 4
Hawryluk P. Kent
DirectorPresident & CEO
Transactions
- Purchase
Common Stock
2025-02-04$10.69/sh+50,000$534,500→ 448,277 total(indirect: By Trust) - Award
Stock Option (Right to Buy)
2025-02-03+243,000→ 243,000 totalExercise: $10.49Exp: 2035-02-03→ Common Stock (243,000 underlying)
Holdings
- 481,397
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.60 to $10.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F3]25% of the shares underlying this option vest and become exercisable on February 3, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on such vesting date.
Documents
Issuer
MBX Biosciences, Inc.
CIK 0001776111
Entity typeother
Related Parties
1- filerCIK 0001673991
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 4:17 PM ET
- Size
- 8.5 KB